Abstract. Sporadic cases of symptomatic hepatitis E virus (HEV) infection have been reported in United States travelers to developing countries, including Mexico and Pakistan. To evaluate the risk of exposure in United States travelers, 356 patients seen in our Travel Clinics were tested for antibodies to HEV before and 6 weeks after traveling. Samples obtained 6 months after traveling were available for 211 travelers. IgG and IgM antibodies to HEV were assayed with HEV ELISA diagnostic kits containing 3 recombinant antigens expressed in Escherichia coli representing immunodominant epitopes within open reading frames 2 and 3 of HEV. Nine patients were IgG seropositive in specimens obtained before travel. Four individuals seroconverted. In all 4 patients, IgG seroconversion was demonstrated in samples obtained at least 6 months after return. Samples obtained 6 weeks after return were seronegative for HEV in all 3 patients for whom such samples were available. Travel destinations were diverse: Thailand, China, Russia, and Peru. These data are consistent with an infection acquired while traveling. None of the seropositive subjects reported any symptoms of hepatitis before or after travel. In the absence of overt disease, these results imply that exposure to HEV resulted in subclinical infections.
Hepatitis E virus (HEV), the primary agent responsible for enterically transmitted non-A, non-B hepatitis, is known to cause sporadic and epidemic disease in Asia 1 , Africa, 2 South America, the Middle East, 3 the former Soviet Union, and Mexico. In endemic countries, HEV infection is a waterborne disease, and transmission occurs by means of fecally contaminated drinking water. 4 In addition to acute and fulminant cases of HEV infection, subclinical infection has also been documented in epidemic situations. Sporadic HEV disease has also been reported in endemic and non-endemic areas, primarily in travelers returning from areas endemic for HEV. 5 Clinical HEV has been described in persons with no history of travel. 6 The mode of transmission in these individuals was not determined, although consumption of contaminated shellfish has been implicated. 7 Our study was performed to define the epidemiology of HEV infection in United States travelers to endemic regions by using a recombinant protein-based test for antibody to HEV to measure seroprevalence and seroconversion rates in patients seen in Travel Clinic populations. Risk factors for anti-HEV seroreactivity were also assessed.
PATIENTS, MATERIALS AND METHODS
Patients were recruited from the Travel Clinics of 2 group practices: Lahey Clinic in Burlington, Massachusetts, and Ochsner Clinic in New Orleans, Louisiana. Prior approval for participation of human volunteers was obtained from the institutional review boards of both institutions. Informed consent was obtained in writing from all subjects. Enrollees were questioned using a physician administered written questionnaire regarding previous travel, medical histories, and immunizations, and, on returning, about possible exposures as well as symptoms of hepatitis. Questions included specific kind of travel (such as urban versus rural, camping versus luxury hotel), exposure to contaminated food and water, as well as sexual or parenteral exposure. Specific symptoms such as fever, gastrointestinal symptoms, and jaundice, including the time of onset and duration, were also asked about. Travel destinations were diverse and included East Asia, Southeast Asia, South Asia, South and Central America, Eastern Europe, and the countries of the former USSR.
Blood samples were obtained before travel and at approximately 6-week and 6-month intervals after return. All three samples were available for 211 subjects. Specimens were obtained before travel and 6 weeks after travel for an additional 145 subjects. For 28 subjects, the only specimens available for assay were those obtained before and 6 months after travel. Serum samples were stored frozen at Ϫ70ЊC until assayed for IgG and IgM antibodies to HEV at a 1/20 dilution, using ELISAs previously described. 8 Samples were tested in batch lots, including pre-travel and at least one post-travel specimen. When additional samples were received, series containing positive samples were retested as a set for confirmation. Three recombinant HEV antigens derived from open reading frames 2 (ORF2) and 3 (ORF3) of Mexican and Burmese isolates were expressed in Escherichia coli as fusions with the 26-kD glutathione-S-transferase protein (GST). The antigens used for screening by ELISA were ORF2 3-2 and ORF3 4-2 as described by Yarbough and others. 9 Bound antibodies were detected with horseradish peroxidase-conjugated goat anti-human IgG or IgM using o-phenylenediamine as substrate and measuring absorbance at 490 nm. A serum sample positive for antibodies to HEV will have an ELISA optical density value Ͼ 0.5 and additionally will be nonreactive with nonrecombinant GST. Sample reactivity was confirmed with recombinant protein SG3 (also from ORF2 and expressed as a GST fusion).
2 All samples were assayed at a 1/20 dilution; SG3 was also assayed at 1/100. Samples having signals within 10% of the cut-off value (0.3) at 1/20 or 1/100 dilutions were scored as indeterminate and were excluded from analysis. Risk factors for seroconversion were assessed using Fisher's 2-tailed exact test.
RESULTS
Of 384 study subjects, 9 (2.3%) were seropositive before travel. All subjects had previous travel histories ( Table 1) . The presence of antibody in persons with prior travel history is consistent with the well-documented observation that HEV antibody can be detected over several years. 10 The overall prevalence of antibody to HEV in United States blood donors without respect to history of travel to HEVendemic regions is 1-2%. 11 Of these initially seropositive travelers, 1 reverted to negative in 6 months. In 2 other individuals, detectable levels of antibody decreased to the equivocal range on the ELISA in post-travel samples. None of the 356 specimens obtained 6 weeks after travel demonstrated seroconversion. Of 236 initially seronegative patients for whom 6-month samples were available, 4 individuals (1.7%) were seropositive for IgG antibody to HEV at 6 months ( Table 2) . IgM antibodies to HEV were not detected in any samples at the 6-month collection time. Presumably, the IgM antibody had waned within that period. Three subjects with indeterminate results were excluded from the analysis. Seroconverters were statistically different (P Ͻ 0.01) from nonconverters with respect to a greater number of developing countries previously visited; more frequent consumption of uncooked foods while traveling; more frequent close contact with natives, including shared meals; and more exposures to human secretions (saliva, stool, and blood). However, because the actual number of seroconverters is small, extrapolation of these results to the traveling public in general would be unreliable at this point but deserves further study.
DISCUSSION
Nine of 384 subjects were seropositive at enrollment into the study. All but 1 person had traveled in the preceding 5 years to a country known to be endemic for HEV. One subject had recently traveled to the Bahamas where HEV has not yet been described.
The apparent rate of exposure (1.7%) to HEV among travelers in this study is low. With a sample size of 356, and given a relatively high pre-travel seropositivity rate of 2.5%, and a slight increase to only 3.7% post-travel, our ability to detect a true difference is only 33.8 or 34%, using a 1-tailed test, at ␣ of 0.05 based on projections using a single proportion for 1 sample. 12 To detect such a small difference, based on an ␣ of 0.05, again using a 1-tailed test, the sample size needed to achieve a ␤ of 0.2 would have had to have been 1,464 (using arcsine approximation). However, it has to be remembered that our study population represents a preselected one that has attended a travel clinic before embarking on their trips and agreed to participate in our study, and may represent a group of travelers who may be better educated and therefore less likely to take unnecessary risks. It is also true that our clinic populations as a whole comprise more business travelers and high-end leisure travelers than backpackers and campers. For these reasons (and possibly others unknown to us at this point), their positive seroconversion rate has been low.
Our study suggests that exposure occurred while traveling to HEV-endemic areas overseas. The risk factor(s) for HEV infection were not identified, although these subjects were exposed to either unsafe water or unsafe food during their travel, which lasted from 1 to 3 weeks. The 4 subjects were either traveling on business or taking short trips on vacation. Unlike patients with clinical hepatitis in whom seroconversion usually occurs 7-8 weeks after exposure, the asymptomatic travelers in this study appeared to seroconvert at a later date. Because asymptomatic HEV infections have not been studied thoroughly, it is not known how characteristic this observation is of subclinical infection. Other possible explanations include a low viral load or a healthier population (compared with infected residents of developing countries) in whom the onset of seroconversion may be delayed. Not unexpectedly, given its transient appearance after infection, IgM antibody to HEV was not detected in any of the seroconverters. In the study by Bryan and others, 1 acutephase human sera were taken 1-12 days after the onset of HEV-related symptoms and convalescent-phase sera were taken between 30 and 90 days after the onset of jaundice. IgM antibodies were detected only in acute-phase sera.
Acute HEV infection has now been reported in 1 individual without any documented recent travel outside the United States. 6 This strain from the United States differed considerably from hepatitis E strains isolated from Burma, Mexico, Pakistan, or China. It has been speculated that this case may represent a zoonotic infection because the sequence of this United States strain was highly homologous to a recently isolated hepatitis E strain from American swine, 13 having 98% and 94% homology at the amino acid level to the second and third open reading frames, respectively. None of the 4 seroconverters in our study population had any exposure to farm animals during the period of study. Study participants were categorized by occupation and none was an agricultural worker.
Two recent studies of seroreactivity to HEV in persons living in nonendemic areas have raised questions about the significance of seroreactivity among United States residents in the absence of even a low rate of clinically defined disease. Mast and others 11 addressed the reasons for the low concordance among different assays for antibodies to HEV when used in low prevalence populations, such as the United States. Potential nonspecific reactivity, differences in antigen formulation, and potential cross-reactivity with other infectious agent(s) are discussed. An unexpectedly high prevalence of antibody to HEV was observed by Thomas and others. 14 The absence of risk factors for infection, the absence of a history of hepatitis, and the absence of a preferred route of transmission in United States blood donors give grounds for caution in interpretation of the data. Further studies are needed to determine the significance of anti-HEV seroreactivity associated with travel.
